Abstract
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.
Highlights
The heptavalent pneumococcal conjugate vaccine (PCV7) schedule in the pediatric population has significantly reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages [1]
After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage
We evaluated the impacts of PCV13 in younger children based on previous studies on the effects of PCV13 on the incidence of invasive pneumococcal diseases, pneumonia, acute otitis media (AOM), and nasopharyngeal carriage
Summary
The heptavalent pneumococcal conjugate vaccine (PCV7) schedule in the pediatric population has significantly reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages [1]. Continuous reduction of IPD cases due to new serotypes included in PCV13 has been observed in all groups of different ages during the first three months after the introduction of PCV13 in 2010. Incidence of IPD caused by nonPCV13 serotypes in 2012-2013 was 13% and 26% that were higher than expected when PCV13 was not available This had only a marginal impact on the global effectiveness of PCV13 because of a significant reduction (about 30,000 cases) in overall IPD incidence and mortality (3,000 deaths) in all groups of different ages. The incidence of IPD caused by the 5 additional PCV13 serotypes 1, 3, 5, 7F, and 19A increased initially by 47% but subsequently decreased by 79%, resulting in an overall 70% reduction during the entire study period (IRR = 0.30; 95% CI, 0.21%–0.44%). In 2012, 67.6% of cases were caused by the non-PCV13 serotypes including 12F (15%), 24F (15%), 22F (7%), and 15B/C (7%)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have